GLP-1 Receptor Agonists May Reduce Insulin Requirements in New-Onset Type 1 Diabetes
{{output}}
Early stage 3 type 1 diabetes is a period of rapid pathophysiologic change. Flagging beta-cell secretion is accompanied by postprandial hyperglucagonemia, impaired incretin amplification, beta-cell stress, and insulin resistance. Incretin-based therapy may ali... ...
